<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062839</url>
  </required_header>
  <id_info>
    <org_study_id>TDAHMEL</org_study_id>
    <nct_id>NCT03062839</nct_id>
  </id_info>
  <brief_title>Melatonin as Adjuvant Treatment for ADHD in Adults</brief_title>
  <official_title>Melatonin as Adjuvant Treatment for ADHD in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of melatonin supplementation as adjuvant treatment in
      ADHD in adults.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adult ADHD Investigator Symptom Rating Scale.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Each of the individual DSM-IV symptoms of ADHD is rated 0 to 3 on a scale of severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>12 weeks</time_frame>
    <description>GAD-7 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>12 weeks</time_frame>
    <description>PHQ-9 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S / I</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical Global Impression Severity / Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Monitoring</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse Event Monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 5 mg taken 30 minutes before bed time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo identical to melatonin capsule taken 30 min before bed time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 5 mg</intervention_name>
    <description>Melatonin 5 mg taken 30 minutes before bed time</description>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Melatonina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male and female age 18-60 inclusive. Primary diagnosis of ADHD AISRS total score ≥ 24 CGI-S
        ≥4 (moderately ill or worse). Understands and is able, willing, and likely to fully comply
        with the study procedures and restrictions.

        Has given written informed consent to participate in the study.

        Exclusion Criteria:

        BMI less than18.5 or greater than 35. Any underlying/ history or current diagnosis of
        systemic and/or metabolic disease (e.g. diabetes, Crohn's disease) and/or neurological
        condition state that may render the subject illegible to participate in the study as
        assessed by medical history, physical exam, clinical and lab evaluation.

        History of uncontrolled hypertension or a resting systolic blood pressure &gt; 140mmHg or
        diastolic blood pressure &gt; 90mmHg (Subjects with well controlled hypertension on a stable
        dose (2 months) of anti-hypertensives will be allowed to participate).

        Major depression or anxiety disorder which is a focus of treatment or requires taking
        medication.

        A lifetime history of psychosis or bipolar disorder Has any concurrent chronic or unstable
        medical condition that could confound with the results of safety assessments, increase risk
        to the subject or lead to difficulty complying with the protocol.

        Subjects taking any medication with CNS effects Subjects with a history of two or more
        prior failed adequate trials of ADHD treatment due to adverse events.

        Use of dietary supplements with potential CNS effect, including omega-3 supplements, 30
        days before study initiation and throughout the study.

        Clinical history of cognitive impairment in judgment of investigator. Pregnant or
        breast-feeding subjects. Women of childbearing potential must have a negative pregnancy
        test performed at screening visit prior to randomization. Women of childbearing potential
        must agree to use adequate birth control for the entire duration of the study.

        Subjects with a current (within the last 3 months) DSM-V diagnosis of alcohol or drug abuse
        or dependence (excluding nicotine).

        Has taken an investigational drug or taken part in a clinical trial within 30 days prior to
        screening.

        Any other reason that, in the opinion of the investigator, prevents the subject from
        participating in the study or compromise the subject safety.

        Previous use of melatonin or melatonin analogues
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mario FP Peres, MD</last_name>
    <phone>2151-0110</phone>
    <email>mariop3r3s@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario FP Peres, MD</last_name>
    <phone>32855726</phone>
    <email>mariop3r3s@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

